While the second Risperdal trial resulted in a verdict favoring drugmaker Janssen Pharmaceuticals, the company was still found negligent in failing to warn—as it was in the first trial—leading some attorneys to speculate that Janssen will focus less on failure to warn defenses and more on the individual facts of each case.

Additionally, observers said that given the different results of each case, and the fact that only two have been tried, it's still too early to definitively predict the direction of the litigation.

The first Risperdal case in Philadelphia concluded with a $2.5 million verdict for the plaintiff, Austin Pledger. In the second trial, the case of plaintiff William Cirba, the jury found that Risperdal was not the cause of the plaintiff's breast growth.